Nuvaira, Inc.

Nuvaira, Inc. has developed an investigational procedure that may have the potential to improve outcomes for patients suffering from obstructive lung diseases.

Visit https://www.nuvaira.com/ for more. is a privately held medical device company that develops minimally invasive products to improve outcomes for patients suffering from obstructive lung diseases by addressing underlying disease pathophysiology. Specifically, Nuvaira has developed a novel, catheter-based system to treat overactive airway nerves, a common disease feature of both COPD and asthma, in a procedure called Targeted Lung Denervation (TLD). Nuvaira received CE Mark approval for its dNerva® Lung Denervation System in January 2016. dNerva Targeted Lung Denervation is an investigative bronchoscopic procedure that disrupts pulmonary nerve input to the lung to reduce the clinical consequences of neural hyperactivity. Mechanistically similar to anticholinergics (the principal class of drugs for treatment of COPD), the one-time TLD procedure can durably reduce acetylcholine release, and thus has the potential to reduce exacerbation risk, improve symptoms, and stabilize lung function. Nuvaira is currently enrolling participants in the AIRFLOW-3 clinical trial. Patients can visit https://airflowtrial.com/ to learn more and see if they qualify to participate. is headquartered in Minneapolis, Minnesota USA and has more than 70 patents issued and pending worldwide.

06/22/2023

Congratulations to Dr. Cumbo-Nacheli and the team at Spectrum Health in Grand Rapids, MI for performing their 9th Targeted Lung Denervation (TLD) treatment in the AIRFLOW-3 Clinical Trial - True Trailblazers!

In recognition of their contribution to the development of therapy for , Nuvaira proudly presented Dr. Cumbo-Nacheli and his team with the Trailblazer Award.

TLD is an investigational procedure using the Lung Denervation System to disrupt pulmonary nerve reflexes, which may have the potential to reduce COPD exacerbations. The AIRFLOW-3 Clinical Trial is enrolling COPD patients in the USA, France, Netherlands, UK, Austria, and Germany.

The dNerva Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

06/16/2023

Congratulations to Dr. Kurman and the Interventional Pulmonary team at the Medical College of Wisconsin in Milwaukee, WI for performing their 1st Targeted Lung Denervation ( ) treatment in the AIRFLOW-3 Clinical Trial!

TLD is a bronchoscopic, investigational treatment using the Lung Denervation System designed to disrupt pulmonary nerve reflexes, which may have the potential to reduce exacerbations. The AIRFLOW-3 Clinical Trial is enrolling COPD patients in the USA, France, Netherlands, UK, Austria, and Germany.

The dNerva Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

06/14/2023

The dNerva Lung Denervation System novel, catheter-based system used to treat overactive airway nerves in a procedure called Targeted Lung Denervation ( ). This investigative technology addresses underlying COPD pathophysiology to help preserve lung health.

Learn which of your patients could be referred to the AIRFLOW-3 pivotal trial: https://lnkd.in/gs3XAZXA

06/07/2023

CONGRATULATIONS to Prof Pallav Shah and the Interventional Pulmonary team at the Royal Brompton and Harefield hospitals in London, UK for performing their 60th Targeted Lung Denervation ( ) treatment today in the AIRFLOW-3 Clinical Trial! An incredible treatment milestone!

TLD is a bronchoscopic, investigational treatment using the Lung Denervation System designed to disrupt pulmonary nerve reflexes, which may have the potential to reduce exacerbations. The AIRFLOW-3 Clinical Trial is enrolling COPD patients in the USA, France, Netherlands, UK, Austria, and Germany.

The dNerva Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

05/31/2023

Do you have a patient that may be a good candidate for the AIRFLOW-3 Clinical Trial? We are enrolling patients in the USA, France, Netherlands, UK, Austria and Germany.

Get more information on patient selection: https://nuvaira.com/patient-selection/

05/16/2023

Congratulations to Dr. Criner and the team at Temple Health in Philadelphia, PA for performing their 50th Targeted Lung Denervation (TLD) treatment in the AIRFLOW-3 Clinical Trial!

is an investigational procedure using the Lung Denervation System to disrupt pulmonary nerve reflexes, which may have the potential to reduce exacerbations. The AIRFLOW-3 Clinical Trial is enrolling COPD patients in the USA, France, Netherlands, UK, Austria, and Germany.

The dNerva Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

05/16/2023

Congratulations to Dr. Eisenmann and the interventional pulmonology team at Universitätsmedizin Halle in Halle, Germany for completing their 9th and 10th Targeted Lung Denervation (TLD) treatments in the AIRFLOW-3 Clinical Trial today!

is a one-time, investigational procedure designed to disrupt pulmonary nerve reflexes, which may have the potential to reduce exacerbations. The AIRFLOW-3 Clinical Trial is enrolling COPD patients in the USA, France, Netherlands, UK, Austria and Germany.

The Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

05/11/2023

Congratulations to Dr. Ghattas and the team at The Ohio State University Wexner Medical Center in Columbus, OH for completing their 15th Targeted Lung Denervation (TLD) treatment in the AIRFLOW-3 Clinical Trial today!

is a one-time, investigational procedure designed to disrupt pulmonary nerve reflexes, which may have the potential to reduce exacerbations. The AIRFLOW-3 Clinical Trial is enrolling COPD patients in the USA, France, Netherlands, UK, Austria and Germany.

The dNerva Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

05/05/2023

Congratulations to Dr. Bhatt and the team at UAB Medicine in Birmingham, AL for performing their 15th Targeted Lung Denervation (TLD) treatment in the AIRFLOW-3 Clinical Trial - True Trailblazers!

is an investigational procedure using the Lung Denervation System to disrupt pulmonary nerve reflexes, which may have the potential to reduce exacerbations. The AIRFLOW-3 Clinical Trial is enrolling COPD patients in the USA, France, Netherlands, UK, Austria, and Germany.

The dNerva Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

04/27/2023

The AIRFLOW-3 Clinical Trial is the first interventional trial targeting exacerbation risk reduction in patients on optimal drug therapy.

Get more information on patient selection and referring patients to a treatment center: https://lnkd.in/gs3XAZXA

04/21/2023

The goal of with the dNerva Lung Denervation System is to improve clinical stability and reduce exacerbations in moderate-to-severe patients with high symptom burden and prior history of exacerbation despite optimal medical management.

https://nuvaira.com/

04/05/2023

A COPDGene long-term study showed that GOLD 2 patients averaged -19mL of lung function loss per year without an exacerbation. Just one exacerbation of any severity resulted in an additional -10mL loss of lung function.

Today, novel therapies such as are demonstrating meaningful and durable reductions in the frequency and severity of COPD exacerbations in patients already on optimal medical management.

Read the full study here: https://lnkd.in/gfCth7aq

Address

Minneapolis, MN

Website

https://nuvaira.com/

Alerts

Be the first to know and let us send you an email when Nuvaira, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Nuvaira, Inc.:

Want your practice to be the top-listed Clinic in Minneapolis?

Nuvaira, Inc.

06/22/2023

06/16/2023

06/14/2023

06/07/2023

05/31/2023

05/16/2023

05/16/2023

05/11/2023

05/05/2023

04/27/2023

04/21/2023

04/05/2023

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category